AMH Clinical Applications

CLINICAL APPLICATIONS OF ANTI-MÜLLERIAN HORMONE (AMH) TESTING

A plain-language overview for non-specialist readers

Anti-Müllerian Hormone (AMH) is a protein produced by tiny follicles in a woman’s ovaries (and, in smaller amounts, by cells in a man’s testes). In women, the amount of AMH in the bloodstream is a direct reflection of how many eggs she has remaining — her “ovarian reserve”. The more follicles, the higher the AMH; as the egg supply dwindles with age, AMH falls.

This simple relationship makes AMH one of the most useful hormones ever discovered for reproductive medicine. A single blood test, taken at any point in the menstrual cycle — unlike older hormone tests which required testing on specific days — gives clinicians a reliable snapshot of a woman’s reproductive potential. That convenience, combined with the test’s accuracy, has driven rapid adoption of AMH measurement across fertility clinics, gynaecology departments, oncology units, and paediatric endocrinology services worldwide.

The antibody technology and immunoassays that made reliable, automated AMH measurement possible were originally developed at Oxford Brookes University. Those assays now underpin the AMH tests sold by Roche, Beckman Coulter, Siemens, and Fujirebio.

1. Measuring Ovarian Reserve

Every woman is born with a finite number of eggs. This number cannot be replenished and declines steadily throughout life. By the mid-thirties the decline accelerates, and by menopause the supply is essentially exhausted. AMH provides the best available blood-based measure of how many eggs remain at any given age.

AMH testing for ovarian reserve is now standard practice in:

• Fertility clinics worldwide, as a first-line assessment before any treatment begins.
• General gynaecology, to counsel women about their reproductive timeline.
• Occupational health and women’s health screening, where women wish to understand their fertility before deciding when to start a family.
• Oncology, before cancer treatment that might damage the ovaries.

No other single blood test provides as much information about ovarian reserve. FSH — the older marker — only rises when the reserve is already severely depleted. AMH begins to fall years earlier, making it a far more sensitive early-warning signal.

2. Egg Freezing (Social and Medical)

Egg freezing (oocyte cryopreservation) has become one of the fastest-growing procedures in reproductive medicine, both for women facing medical threats to their fertility and for those choosing to delay childbearing for personal or professional reasons.

AMH is central to egg-freezing practice in two ways:

• Patient selection: identifying which women have sufficient ovarian reserve to make egg freezing worthwhile, and which may need to act urgently before their reserve declines further.
• Predicting yield: women with higher AMH levels typically produce more eggs per stimulation cycle, allowing clinicians to counsel women realistically about how many eggs they are likely to retrieve.

As social egg freezing grows — driven by lifestyle trends and increasing employer-funded fertility benefits, particularly in the US, UK, and Asia — the demand for AMH testing as a prerequisite assessment grows with it.

3. Personalising IVF Treatment — Selecting the Right FSH Dose

In vitro fertilisation (IVF) requires stimulating the ovaries with injections of follicle-stimulating hormone (FSH) to produce multiple eggs in one cycle. Getting the dose right is critical: too low a dose produces too few eggs, while too high a dose risks ovarian hyperstimulation syndrome (OHSS), a potentially serious complication.

AMH has transformed FSH dosing from a largely intuitive process into an evidence-based, personalised approach. Studies consistently show that AMH level is the single best predictor of how the ovaries will respond to stimulation. Clinical algorithms now use AMH to assign women to low, standard, or high stimulation protocols before their first injection is given.

The practical benefits are substantial: fewer cancelled cycles, fewer hospitalisations for OHSS, better egg yields, and lower overall treatment costs. This use of AMH is now embedded in IVF protocols at the majority of fertility units globally.

4. Diagnosing Disorders of Sexual Development (DSD) in Children

In newborns and young children where the sex of the child is unclear from external appearance — a disorder of sexual development (DSD), formerly known as intersex — knowing whether functional testicular tissue is present is medically urgent.

In male infants, Sertoli cells in the testes produce AMH from birth onwards. In female infants, ovaries produce very little AMH before puberty. This means:

• A high AMH level in a child with ambiguous genitalia is strong evidence that testicular tissue is present, even if the testes cannot be felt or seen.
• A very low or undetectable AMH confirms the absence of functional testicular tissue.

AMH measurement has become a standard investigation in paediatric endocrinology for exactly this reason. It is non-invasive, requires only a blood test, and provides clear guidance where imaging and other tests may be inconclusive.

5. Diagnosing Polyendocrine Metabolic Ovarian Syndrome (PMOS)

Important terminology update: In May 2026, following a landmark global consensus process involving 56 international organisations and published in The Lancet, polycystic ovary syndrome (PCOS) was officially renamed polyendocrine metabolic ovarian syndrome (PMOS). Both names will be in circulation during a three-year transition period.

PMOS/PCOS is the most common hormonal disorder in women of reproductive age, affecting roughly 1 in 8 women worldwide — approximately 170 million people globally. AMH levels are typically two to three times higher in women with PMOS than in healthy controls, making it a powerful diagnostic marker.

• Roche has received CE marking for the use of its Elecsys AMH assay specifically in the diagnosis of PMOS/PCOS — a significant regulatory milestone.
• In adult women of reproductive age, AMH demonstrates strong diagnostic accuracy for PMOS.
• In adolescents, AMH is less reliable as a standalone PMOS marker; guidelines recommend caution in this age group.

Because PMOS is associated with long-term metabolic risks — including type 2 diabetes, cardiovascular disease, and endometrial cancer — earlier, more accurate diagnosis opens the door to earlier intervention.

6. Diagnosing Premature Ovarian Insufficiency and Premature Ovarian Failure

Premature ovarian insufficiency (POI) occurs when the ovaries begin to fail before the age of 40. If untreated, it progresses to premature ovarian failure (POF) — the complete and permanent cessation of ovarian function before 40. Both conditions cause infertility, menopausal symptoms in young women, and long-term health risks including osteoporosis and cardiovascular disease.

The current standard diagnostic test for POI and POF is FSH, but FSH only rises significantly once ovarian failure is already well established. AMH falls much earlier in the disease process, providing a window for earlier identification and intervention.

A major real-world study published in 2026 in Frontiers in Endocrinology (Mao et al., n = 1,106 women) demonstrated that AMH achieved an AUC of 0.885 for POI and 0.872 for POF — both well above the “good” diagnostic threshold of 0.8. Combined with oestradiol, accuracy rose to 0.91 for both conditions. The authors concluded that AMH should be integrated into routine clinical screening for early ovarian dysfunction.

7. Oncofertility — Protecting Fertility in Women with Cancer

Cancer treatments — chemotherapy, radiotherapy, and surgery — can cause irreversible damage to the ovaries. AMH has become a central tool in oncofertility, the specialty that bridges cancer care and fertility preservation, and is used at three stages of the cancer journey:

• Before treatment: an AMH test quantifies ovarian reserve and guides urgent referral for egg or embryo freezing.
• During and after treatment: serial AMH measurements track the impact of chemotherapy on the ovaries in real time.
• Long-term follow-up: AMH helps assess whether ovarian function has recovered and informs decisions about hormone replacement therapy and fertility treatment.

Given that cancer survival rates have improved dramatically and hundreds of thousands of women of reproductive age are diagnosed with cancer each year, oncofertility is one of the fastest-growing areas of clinical AMH use.

8. Monitoring Granulosa Cell Tumours of the Ovary

Granulosa cell tumours (GCTs) are a rare type of ovarian cancer that arises from the same granulosa cells that produce AMH in healthy follicles. Because these tumour cells retain the ability to secrete AMH, blood AMH levels are directly proportional to the size and activity of the tumour, making AMH a near-perfect tumour marker:

• Before surgery: a markedly elevated AMH in a woman with an ovarian mass strongly suggests a granulosa cell tumour, helping to plan the appropriate surgical approach.
• After surgery: AMH should fall to normal levels if the tumour has been completely removed. A persistently elevated post-operative AMH indicates residual disease.
• During follow-up: GCTs can recur 10, 20, or even 30 years after apparently successful surgery. AMH rises in the bloodstream months or years before recurrence becomes detectable on imaging, enabling earlier treatment and better outcomes.

9. Predicting Bone Loss and Osteoporosis Risk

Because AMH tracks the rate of ovarian ageing, research has shown that AMH levels can predict which women are likely to experience accelerated bone loss. Women with low AMH in their late thirties or early forties are approaching menopause sooner than average, and studies show their bone mineral density is already declining at this earlier stage.

AMH therefore offers a potential early warning tool to identify women who would benefit from earlier intervention — such as hormone replacement therapy, calcium supplementation, or weight-bearing exercise programmes — before fractures occur. This is currently an area of active research rather than established clinical practice, but the evidence base is growing.

10. Emerging Applications in Male Health

In males, AMH is produced by Sertoli cells in the testes from foetal life through puberty and into adulthood. Research is increasingly revealing its clinical value in men:

• Assessing testicular function in boys: AMH is an excellent marker of Sertoli cell function in prepubertal boys, providing information even before puberty when testosterone levels are not yet informative.
• Evaluating male infertility: studies have found associations between AMH levels and sperm parameters including sperm count and quality.

Predicting response to fertility treatment: AMH may help identify which men with low sperm counts are likely to respond to hormonal treatment and which require surgical sperm retrieval.

Summary: Clinical Applications at a Glance

Clinical Application	Current Status
Ovarian reserve assessment	Established standard of care worldwide
Egg freezing protocols	Established – standard pre-procedure test
IVF FSH dose personalisation	Established – embedded in most IVF protocols globally
Paediatric DSD / intersex diagnosis	Established standard in paediatric endocrinology
PMOS (formerly PCOS) diagnosis	CE approved (Roche); growing clinical adoption in adult women
Premature ovarian failure (POI/POF)	Strongly evidenced; increasing clinical uptake
Oncofertility — pre-cancer treatment	Established and growing rapidly
Granulosa cell tumour monitoring	Established preferred tumour marker for GCTs
Bone loss / osteoporosis prediction	Emerging — active research phase
Male infertility / testicular function	Emerging — research phase, growing evidence

Conclusion: The AMH Market Will Continue to Grow

The breadth of clinical applications described above reflects a hormone assay that is still in the relatively early stages of its clinical life. Many of the applications outlined here — PMOS diagnosis, premature ovarian failure screening, oncofertility, bone loss prediction, male infertility — are either newly established or still emerging.

Several structural factors point strongly to continued market growth: rising infertility rates globally; the renaming of PCOS to PMOS and its recognition as a systemic metabolic disorder affecting 170 million women worldwide; Roche’s CE approval for PMOS diagnosis; improving cancer survival rates driving greater oncofertility need; growing awareness of ovarian ageing for long-term health; and automation and cost reduction making AMH testing increasingly accessible in lower- and middle-income countries.

The great majority of the clinical research described above — across all ten applications — has been conducted using one of the automated AMH assays built on antibody technology developed at Oxford Brookes University. It is this foundational science that has enabled AMH testing to move from the research laboratory into routine clinical practice worldwide.